Diabetes Research: Open Access

Diabetes Research: Open Access

Hiroshi Bando^1,2iD*
1Medical Research/Tokushima University, Tokushima, Japan
²Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan

Corresponding Author: Hiroshi Bando ^{ORCID iD}
Address: Tokushima University /Medical Research, Nakashowa 1-61, Tokushima 770-0943, Japan.
Received date: 16 June 2024; Accepted date: 15 July 2024; Published date: 22 July 2024

Citation: Bando H. Recent Research Development of Imeglimin as Oral Hypoglycemic Agent (OHA). Diab Res Open Access. 2024 Jul 22;5(1):13-16.

Copyright © 2024 Bando H. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.

Keywords: Oral Hypoglycemic Agent, Imeglimin, Twymeeg, Gastrointestinal Adverse Effects, Hemodialysis, Drug Delivery System

Abbreviations: OHA: Oral Hypoglycemic Agent; GI-AEs: Gastrointestinal Adverse Effects; HD: Hemodialysis; DDS: Drug Delivery System

Abstract

As a novel oral hypoglycemic agent (OHA), imeglimin (Twymeeg) has recently been introduced into clinical practice. It has shown improved glucose variability via a mitochondrial mechanism. Adequate daily doses identified in several investigations are 1000 mg or 1500 mg twice a day (BID). Consequently, 1000 mg BID seems to be recommended in light of tolerability, safety, and gastrointestinal adverse effects (GI-AEs). For hemodialysis (HD) patients, 500 mg/day was tried with clinical effect. To minimize GI-AEs, novel research has explored the adaptation of nanofiber disintegration for the drug delivery system (DDS). This method takes only 2 +/- 1 seconds via buccal route administration.